Impaired angiogenic responses to ischemia characterize the vascular complications associated with diabetes. Diabetic foot ulcers in the presence of ischemia are associated with the most severe outcomes, including a higher rate of mortality and lower probability of healing. Specific micro-RNAs (miRNAs) such as miRNA-200b have been shown to negatively regulate angiogenesis in ischemia. Therefore, we sought to investigate miRNA-200b as a target and biomarker of diabetes-impaired angiogenesis. To assess the importance of miRNA-200b in diabetes-impaired angiogenesis, we transfected endothelial cells with anti-miRNA-200b or anti-miRNA-Neg then performed a functional tubulogenesis assay under high glucose and hypoxic conditions. High glucose impaired tubule formation by 23.6% in response to hypoxia when compared to controls (51.9±15.4 vs. 39.7±23.2, P<0.005), this decrease was prevented by anti-miRNA-200b treatment. Furthermore, in an in vivo hind-limb ischemia model, diabetic mice (n=8-11/group) were injected intramuscularly with anti-miRNA-200b or anti-miRNA-Neg at the time of hind-limb ischemia surgery. Diabetes impaired blood flow reperfusion was assessed by laser Doppler perfusion imaging (LDPI) in anti-miRNA-Neg control mice (LDPI: 0.27), and this was rescued by inhibition of miRNA-200b to nondiabetic levels (LDPI: 0.41, P<0.05). To assess the utility of miRNA-200b as a biomarker of delayed healing, plasma miRNA-200b was measured in a rodent excisional wound model. When compared to controls, diabetes elevated plasma miRNA-200b in both unwounded and wounded animals, suggesting a diabetes related change. Whether this change is seen in humans remains to be investigated.

In conclusion, this study has identified that miRNA-200b is a potential target of diabetes-impaired angiogenesis as shown in this preclinical model of predominant ischemia in a diabetes setting.


C. Cannizzo: None. E. Solly: None. L.F. Olaya: None. M. Abdollahi: None. S.S. Sutanto: None. S.M. Twigg: Advisory Panel; Self; Abbott, AstraZeneca, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Novo Nordisk Inc., Roche Diabetes Care, Sanofi. C. Bursill: None. J.T. Tan: None. S. McLennan: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at